For the quarter ended June 2026, BillionToOne (BLLN Quick QuoteBLLN - Free Report) reported revenue of $109.45 million, representing no change compared to the same period last year. EPS came in at $0.15, compared to $0 in the year-ago quarter.

The reported revenue represents a surprise of +0.57% over the Zacks Consensus Estimate of $108.83 million. With the consensus EPS estimate being $0.15, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how BillionToOne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total tests delivered: 196,000 compared to the 194,775 average estimate based on two analysts.
• Overall ASP: $551.00 versus $554.26 estimated by two analysts on average.
• Revenue- Clinical Trial Support and Other Services: $1.5 million compared to the $1.22 million average estimate based on three analysts.
• Revenue- Prenatal: $94.2 million versus $96.49 million estimated by three analysts on average.
• Revenue- Oncology: $13.7 million versus the three-analyst average estimate of $11.4 million.

View all Key Company Metrics for BillionToOne here>>>

Shares of BillionToOne have returned +20.5% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.